Physician profile
Robert E Smith
NPI 1578675633
$1,235.77
in general payments reported to CMS, 2019-2025
15 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $125 · 2021: $64.22 · 2022: $27.29 · 2023: $340 · 2024: $235 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $249.59 | 2023-2024 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $159.92 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.96 | 2019 | |
| Abbvie INC. | $139.39 | 2022-2025 | Lumigan, Vuity |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $91.71 | 2019 | |
| Amgen INC. | $79.93 | 2019-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $62.30 | 2024-2025 | Xdemvy |
| Allergan, INC. | $47.05 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $47.01 | 2023 | Xeomin |
| Kala Pharmaceuticals, INC. | $24.62 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.35 | 2023 | Quviviq |
| Welch Allyn | $19.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.00 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.